California-based healthcare solutions provider Omnicell, Inc. OMCL reported first-quarter adjusted earnings per share of 19 cents (considering stock-based compensation as a regular expense), unchanged from the year-ago number. Adjusted earnings, however, surpassed the Zacks Consensus Estimate by 5 cents.
On a reported basis, Omnicell's net income was $6.3 million or 17 cents per share, compared to $6.2 million or 17 cents per share recorded in the year-ago quarter.
Revenues in Detail
Revenues increased 14.2% year over year to $116.2 million in the quarter, exceeding the Zacks Consensus Estimate of $111 million.
On a segmental basis, during the quarter, the company’s Automation and Analytics segment contributed $92.8 million to its sales, up 13.9% year over year. The company encouragingly noted that, during the quarter, 52% of its orders in the Automation and Analytics segment of the business were from new and competitive conversion customers globally.
The Medication Adherence segment contributed $23.4 million in revenues, up 15.3% from the year-earlier quarter.
In addition, the company's investments in its 3-legged strategy of differentiated products, expansion in new markets, and acquisition and partnerships, drove the revenue upside during the first quarter.
Operational Update
Omnicell's adjusted gross profit during the reported quarter improved 13.4% to $62.6 million. However, gross margin contracted about 40 basis points (bps) to 53.8% in the quarter.
Adjusted operating expenses in the quarter increased 14.2% to $47.3 million. Although adjusted operating profit in the quarter improved 11.2% year over year, adjusted operating margin contracted 40 bps to 13.1% in the reported quarter.
Financial Update
Omnicell exited the quarter with cash and cash equivalents of $139.6 million, up 10.9% from $125.8 million at the end of 2014.
Outlook
Omnicell also provided an update on its full year 2015 guidance. After including the expected results from the company’s recent acquisitions of MACH4 Pharma Systems and Avantec Healthcare Ltd., the company currently expects full year revenues in the range of $495−$510 million, representing annualized growth of 12% to 16% (from earlier range of $480−$490 million, growth of 9% to 11%). The current Zacks Consensus Estimate of $503 million falls at the midpoint of the range.
However, full year adjusted earnings is forecast in the band of $1.31 to $1.36 per share including both acquisitions (earlier $1.35–$1.40). The current Zacks Consensus Estimate for EPS of 99 cents falls far below the guided range.
Our Take
Omnicell reported a better-than-expected first-quarter 2015 with both the top and the bottom line surpassing the respective Zacks Consensus Estimate. According to the company, with the successful implementation of its three growth strategies, viz. compellingly differentiated products, expansion into new markets and targeted acquisition, it has successfully doubled its revenues and tripled its profits over the past five years.
Moreover, strategic acquisitions are expected to add values to the company’s growth. Earlier this month, the company completed the acquisition of MACH4 Pharma Systems (Germany) and Avantec Healthcare (U.K.). The acquisition of Surgichem has also expanded Omnicell’s leadership capabilities in medication adherence in the U.K.
While Omnicell continues to focus on the Middle East, the U.K. and China, we are impressed with the company’s initiative to increase product adoption rate in other parts of the world too. We believe Omnicell remains high on a customer's demand list, given the improved efficiency and safety capabilities of the technologies offered by it.
We are also impressed with the long-awaited investigation results, related to certain whistleblower allegations that had postponed the company’s 10K filing, coming in favor of Omnicell. In view of that, Omnicell also regained the Nasdaq listing compliance.
Zacks Rank
The stock currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector are Medidata Solutions, Inc. MDSO, Merge Healthcare Incorporated MRGE and Foundation Medicine, Inc. FMI. While Medidata sports a Zacks Rank #1 (Strong Buy), Foundation Medicine and Merge hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment